Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $1.49M a year earlier. Trailing-twelve-month stock-based compensation was $1.44M.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $359.27K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$1.44M-63.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

Mixed currencies · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -63.8% is the lowest of 9, against a peer median of +26.5%.
EPRX Competitors
Stock-Based Compensation for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$15.21M USD———
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.04M USD-48.6%-13.0%—
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M USD+16.7%-17.0%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M USD+122.7%+4.3%—
MDWDMediWound Ltd.LTM Mar 2026$2.91M USD-16.2%+16.9%20.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$2.64M USD+336.0%+112.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding EPRX) —+26.5%+10.6%312.1%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(18.18M)(18.99M)(21.81M)(25.74M)(39.22M)
Depreciation & Amortization88.17K147.89K117.1K171.72K241.68K
Deferred Income Tax00000
Stock-Based Compensation01.43M1.06M3.22M0
Change in Working Capital(167.16K)1.51M4.03M(6.76M)(725.6K)
Accounts Receivables150.92K230.48K(78.09K)(101.39K)(438.64K)
Inventory00000
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(318.07K)(39.96K)3.67M(5.95M)(2.69M)
Other Non-Cash Items6.68M1.5M977.18K(880.5K)10.68M
Operating Cash Flow(11.58M)(14.4M)(15.62M)(29.99M)(29.03M)
Capital Expenditures(341.28K)(235.55K)(55.25K)(104.23K)(598.77K)
Acquisitions (Net)00000
Purchases of Investments(7.12M)(3.27M)000
Sales of Investments013.34M000
Other Investing Activities(3.97M)242029.07K0
Investing Cash Flow(11.42M)9.83M(55.25K)(75.16K)(598.77K)
Debt Repayment9.62M(142.27K)(59.81K)(9.14M)0
Common Stock Issued29.91M10.64M11.96M54.56M77.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(69.33K)306.77K3.97M363.06K0
Financing Cash Flow39.46M10.8M15.87M45.78M77.33M
Effect of Forex Changes(63.69K)(507.4K)618.45K(1.96M)(403.1K)
Net Change in Cash16.4M5.73M811.93K13.76M47.3M
Free Cash Flow(11.92M)(14.63M)(15.68M)(30.1M)(29.63M)

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.